Eisai follows family ties with name for newly approved Alzheimer's drug Leqembi
The road to approval for Alzheimer’s drug Leqembi began more than a decade ago when Eisai and Biogen collaborated on a first trial for what was then called BAN2401. The amyloid beta-directed therapy went through years of study before lecanemab became its recommended international non-proprietary (INN) name in September 2020.
Last week, the FDA greenlit the infused drug and it became officially recognized by its proprietary brand Leqembi.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.